表紙
市場調查報告書

中樞神經系統 (CNS) 治療藥的全球市場

CNS Therapeutics

出版商 Global Industry Analysts, Inc. 商品編碼 53589
出版日期 內容資訊 英文 978 Pages
商品交期: 最快1-2個工作天內
價格
中樞神經系統 (CNS) 治療藥的全球市場 CNS Therapeutics
出版日期: 2020年01月01日內容資訊: 英文 978 Pages
簡介

全球中樞神經系統 (CNS) 治療藥的市場規模預計在2025年前達到1377億美元的規模。治療各種神經病變──癲癇,偏頭痛,阿茲海默症,帕金森氏症,多發性硬化症,思覺失調症等──的未滿足需求急速提升,且對於這些疾病的快速支援需求成為市場成長的一大要素。另一方面,開發有效和安全的療法需要時間,導致開發速度和市場增長率下降。就各地區來看,新興市場預計將迅速增長,美國和歐洲國家佔全球總數的70%,而中國市場的複合年增長率(CAGR)為7.3%。

本報告提供全球中樞神經系統 (CNS) 治療藥市場相關調查,彙整市場概要和競爭趨勢,產品概要,各地區的趨勢,及加入此市場的主要企業的簡介等資料。

第1章 簡介,調查方法·範圍

第2章 摘要整理

  • 產業概要
    • 中樞神經系統 (CNS) 治療藥:序論
    • 中樞神經系統治療:患者增加,市場機會擴大
    • FDA批准的CNS治療清單(2018、2019)
    • 主要藥品專利到期給市場帶來壓力
    • 發達國家繼續壟斷市場
    • 發展中國家市場的快速發展
  • 不同治療分類的市場分析
    • 抗癲癇藥
    • 中樞神經系統 (CNS) 疼痛管理
    • 抗老年癡呆症藥
    • 抗帕金森氏症藥
    • 抗憂鬱劑
    • 抗精神病藥
    • 其他中樞神經系統疾病 (多發性硬化症,ADHD (注意缺陷多動障礙(簡稱過動症)),失眠症)
  • 主要企業
    • AbbVie Inc. (美國)
    • Alkermes Plc. (愛爾蘭)
    • Allergan Plc. (愛爾蘭)
    • AstraZeneca Plc. (英國)
    • BIAL Group (葡萄牙)
    • Bristol-Myers Squibb (美國)
    • Eisai (日本)
    • Endo Pharmaceuticals Inc. (美國)
    • Eli Lilly and Co. (美國)
    • F. Hoffmann-La Roche Ltd. (瑞士)
    • Fabre-Kramer Pharmaceuticals, Inc. (美國)
    • GlaxoSmithKline (英國)
    • H. Lundbeck A/S (丹麥)
    • Johnson & Johnson (美國)
    • Janssen Pharmaceuticals, Inc. (美國)
    • Merck & Co., Inc. (美國)
    • Neurocrine Biosciences, Inc. (美國)
    • Novartis AG (瑞士)
    • 大塚製藥 (日本)
    • Pfizer, Inc. (美國)
    • Purdue Pharma L.P. (美國)
    • Sanofi (法國)
    • 大日本住友製藥 (日本)
    • Sunovion Pharmaceuticals, Inc. (美國)
    • 武田藥品工業 (日本)
    • Teva Pharmaceutical Industries Ltd. (以色列)
    • UCB S.A., (Belgium) 131
  • 市場趨勢與推動因素
  • 全球市場的未來展望

第3章 市場分析

  • 各地區的市場分析
  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲 (法國,德國,義大利,英國,西班牙,俄羅斯等)
  • 亞太地區 (澳洲,印度,韓國等)
  • 南美 (阿根廷,巴西,墨西哥等)
  • 中東 (伊朗,以色列,沙烏地阿拉伯,UAE等)
  • 非洲

第4章 市場競爭

  • 企業分析:全157公司份 (包含公司內部部門/子公司181公司份)

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-1835

The global market for CNS Therapeutics is projected to reach US$137.7 billion by 2025, driven by the urgent need to address the unmet medical needs of neurological disorders. Diseases of the brain and mind range from epilepsy, stroke, migraine, Alzheimer's, Parkinson's, dementia, multiple sclerosis, brain injuries, neuroinfections, schizophrenia, psychosis and other mental disorders. With unmet needs continuing to persist, societal and healthcare burden continues to increase. Stroke and infections such as meningitis and encephalitis continue to be the leading cause of disability worldwide, pushing up the cost of nursing care, hospice and bringing down quality of life. The unmet needs are evident in all phases of drug development i.e. identification of therapeutic targets; optimization of lead compounds; gaps in toxicity and pharmacokinetics studies; and slow resolution of ethical issues, among others. The need of the hour is innovation in developing more potent drugs and therapies. One of the reasons for the slower development of safe and effective drugs for neurology is the fact that the human brain is one of the most complex and highly organized organs in the universe. The brain is a highly sophisticated piece of organic system perfected over millions of years of evolution. Scientists continue to struggle to fathom the complex interaction of chemicals and neurons in the brain. Investments in drug development in neurology is risky since certain diseases like neuropsychiatric diseases are difficult to target, are poorly defined, cannot be easily assayed, and pose challenges in efficiently validating clinical efficiency of drugs during clinical trials as most diseases progress slowly and develop over the years.

Strong opportunities for CNS focussed drugs therefore exists and compounding this need is the rapidly aging population and a parallel rise in Parkinson's, Alzheimer's, pain manifestations, cerebrovascular disorders, stroke, seizures, cognitive and memory disorders. The scenario has created a healthy global pipeline of late stage drugs and the market is expected to benefit from rising acceptance of new therapies and new classes of drugs; increased demand for combination therapies; growing use of generics; and launch of new Alzheimer's drugs including anti-amyloid proteins, cholinergic and nicotine receptor agonists, neuro protective drugs, vaccines and GABA receptor modulators. Better understanding of the electrochemical processes of the brain and development of disease-modifying therapies is driving growth in the antiepileptic drugs market. Combination CNS Therapies are especially gaining prominence for their ability to target multiple pathologic processes simultaneously. Volume of CNS prescriptions for chronic pain and psychiatric disorders will grow in the coming years as the burden of mental illnesses intensifies as a result of lifestyle and societal changes and physiological stress. The growing focus on healthcare cost containment and rationalization and legislation of policies that encourage physician prescription of generic drugs will encourage sales of generic CNS medications. A key trend in the market is pharma companies' efforts to restrategize CNS drug development, which still continues to cost significantly higher than development costs in other therapeutic areas. Increased use of contract research organization services; and predictive planning to prevent late stage drug failure are few of the strategies adopted to infuse vigor in the CNS drug development space. The United States and Europe represent large markets worldwide with a combined share of 70% of the market. China ranks as the fastest growing market with a CAGR of 7.3% over the analysis period supported by factors such as changing social structures and increased risk of developing psychiatric disorders such as schizophrenia, sleep disorders, depression and anxiety; growing literacy rates, improved awareness and gradual reduction in the stigma associated with neurological disorders; and government policy led development of healthcare delivery systems.

Competitors identified in this market include, among others, Alkermes Plc., Allergan Plc., AstraZeneca Plc., Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Janssen Pharmaceuticals Inc., Merck & Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi, Sunovion Pharmaceuticals Inc.,Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., UCB S.A.

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Central Nervous System (CNS) Therapeutics: A Prelude
  • CNS Therapeutics Exhibit Robust Opportunities amidst Rising Incidence of CNS Disorders
  • List of FDA Approved CNS Drugs: 2019
  • List of FDA Approved CNS Drugs: 2018
  • Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market
  • Patent Expiries of Leading CNS Drugs: 2008-2022
  • Developed Markets to Maintain their Dominance
  • Developing Market to Drive the Market Momentum
  • MARKET ANALYSIS BY THERAPEUTIC CATEGORY
  • Anti-Epilepsy Market
  • Global Market Overview
  • Regional Landscape
  • Developed Countries Account for a Major Share of Epilepsy Treatment
  • Developing Countries Struggle with Low Treatment Rates
  • New Approvals (2019 and 2018)
  • Disease Overview
  • Epilepsy Incidence by Type (2019): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy
  • Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy
  • High Unmet Needs Offer Scope for Market Growth
  • Treatment
  • Anti-Epileptic Drugs (AEDs) by Generic Name and Brand Names
  • Leading Anti-Epileptic Drugs
  • Leading Anti-Epileptic Drugs and Their Mechanism of Action
  • Patent Expiries of Major Anti-Epilepsy Drugs
  • FDA's New Policy for AED Drugs to Bolster Market Growth
  • AAN Updated Guidelines on New AEDs Use for Treating New Onset Epilepsy (2019)
  • Select Currently Available Epilepsy Drugs
  • Select Anti-Epilepsy Drugs (AEDs) in Phase III Trials
  • Innovative Drugs Needed for Better Treatment Compliance
  • Abounding Potential for NCEs
  • A New Research Demonstrates Effectiveness of Gluconate in Treating Neonatal Seizures
  • FDA Approves Epidiolex (Cannabidiol) - First Drug for Treating Dravet Syndrome and Lennox-Gastaut Syndrome
  • Refractory Childhood Epilepsy & Pregnancy Epilepsy - Major Concerns
  • Recent Approvals for Childhood Epilepsy: 2016-2019
  • Review of Anti-Epilepsy Drugs
  • Vimpat(r)
  • Keppra(r)
  • Lamictal
  • Tegretol(r)
  • Sabril(r)
  • Perampanel
  • Zonegran(r)
  • Topamax(r)
  • Trileptal(r)
  • Neurontin(r)
  • Lyrica(r)
  • Depakine(r)
  • CNS Pain Management
  • Market Overview
  • Treatment
  • Drugs Indicated for Pain Management
  • Select Phase III Ongoing Studies for Cancer Pain
  • Regional Overview
  • Players
  • Combination Therapies Gain Prominence
  • Key Trends in Chronic Pain Management
  • Neuropathic Pain Management: Market with High Potential
  • Select Phase III Ongoing Studies for Neuropathic Pain
  • Lyrica's Generics Gain FDA Approval
  • Migraine Market: A Core Vertical in CNS Pain Management
  • Migraine Care: Select Patent Expiries (2013-2015)
  • Migraine Completed Phase III Studies: As of October 2019
  • Migraine Ongoing Phase III Studies: As of October 2019
  • Select Pain Management Drugs
  • Flupirtine
  • Lyrica(r)
  • Oxycodone
  • Nucynta ER
  • Metabotropic Glutamate Receptors (mGluRs)
  • New Pain Management Drugs
  • Novartis Presents New Data for Aimovig
  • Reyvow, Eli Lilly's Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
  • Three New Migraine Drugs Obtain FDA Approval
  • Eli Lilly's Emgality Receives FDA Approval
  • Anti-Alzheimer's
  • Market Overview
  • Global Alzheimer's Prevalence by Age Group
  • Alzheimer's Phase III Completed Studies
  • Alzheimer's Phase III Ongoing Studies
  • Treatment for Alzheimer's
  • Select Leading Drugs for Alzheimer's Disease by Drug Category
  • Patent Expiries of Leading Alzheimer's Drugs
  • Aducanumab Marches towards FDA Approval, Following being Abondoned by Biogen a few Months Ago
  • The Clinical Trials for Aducanumab
  • Aducanumab: A Promising Drug Which would Revolutionalize the Alzheimer's Market
  • Alzheimer's Drugs: A Market Plagued with Failures
  • Promising Compounds with Silver Lining
  • PRI-002 Gains Success in First Stage of Human Testing for Alzheimers Disease
  • Updated FDA Standards Make Way for Increased Alzheimer's Drug Testing
  • Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
  • Elenbecestat's Phase 3 Trials Halted
  • Novel Drug Delivery Method to the Brain Discovered
  • Alzheimer's Association Provides Grant to Longeveron
  • BPN14770 Demonstrates Potential to Protect Against Alzheimer`s Symptoms
  • A Review of Select Anti-Alzheimer's Drugs
  • Aricept
  • Exelon
  • Reminyl
  • Ebixa
  • Namenda
  • A Review of the Alzheimer 's disease
  • Alzheimer's Effect on Brain
  • Causes for Alzheimer's
  • Who Are at Risk?
  • Prevalence of Alzheimer's Disease
  • Diagnosis of Alzheimer's
  • Anti-Parkinson's
  • Market Overview
  • Select Top Selling Drugs for Parkinson's Disease
  • Nourianz, An Add-on Medication for Treating Episodes of Parkinson's Disease Secures FDA Approval
  • Recent Approvals
  • Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD
  • Xadago - Add-On Therapy for Parkinson's Disease
  • NUPLAZID(r) - The First and the Only Approved Drug for Psychosis related to Parkinson's disease
  • Parkinson's Phase III Completed Studies: As of October 2019
  • Parkinson's Ongoing Phase III Studies: As of October 2019
  • Select Anti-Parkinson's Drugs
  • Levodopa
  • Dopamine Agonists
  • Mirapex
  • FDA Announces Imminent Discontinuation of Certain Formulations of GSK's Requip for PD and RSL Treatment
  • A Review of the Parkinson's Disease
  • Prevalence
  • Symptoms
  • Causes
  • Diagnosis
  • Anti-Depressants
  • Market Overview
  • Anti-Depressant Market: Percentage Share Breakdown by Depressive Disorder Type
  • Anti-Depressant Treatment
  • Select Top Selling Anti-Depressants in 2018
  • Select Antidepressant Drugs
  • Zoloft (Sertraline)
  • Cymbalta(r)
  • Prozac (Fluoxetine)
  • Effexor (Venlafaxine)
  • Paxil
  • Wellbutrin (Bupropion)
  • Recent Approvals of Anti-Depressants
  • Esketamine, the Fast Acting Drug for Depression from Janssen Receives FDA Approval
  • Pipeline Drugs in Phase III for Depressive Disorder: As of October 2019
  • A Review of Depression
  • Prevalence of Depression
  • Causes of Depression
  • Types of Depressive Disorders
  • Available Treatment
  • Tricyclic Antidepressants
  • Monoamine Oxidase Inhibitors
  • Lithium Salts
  • Working of Antidepressants
  • Ranking of Antidepressants in Terms of Efficacy
  • Types of Antidepressants
  • NMDA Receptor Antagonists
  • NMDA Receptor (NMDAR)
  • NMDA Receptor Agonists
  • Acetylcholinesterase Inhibitors
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Workings of SSRIs
  • Safety Levels of SSRI Drugs
  • Adverse Effects of SSRI
  • Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)
  • Anti-Psychotics
  • Market Overview
  • Leading Atypical Antipsychotics for the Treatment of Schizophrenia
  • Pipeline Drugs in Phase III for Schizophrenia: As of October 2019
  • Pipeline Drugs in Phase III for Bipolar Disorder: As of October 2019
  • Select Anti-Psychotic Drugs
  • Zyprexa
  • Seroquel
  • Abilify
  • Clozaril
  • Risperdal
  • Risperdal(r) Consta(r)
  • Geodon
  • Invega Sustenna
  • Saphris
  • Latuda
  • A Review of Anti-Psychotics
  • Indications of Antipsychotics
  • An Effective Adjunctive Therapy
  • Off-label Uses
  • Efficacy - Marred by Lack of Evidence Base
  • Types of Antipsychotics
  • Difference between Typical and Atypical
  • Atypical Antipsychotics Up Against Typicals
  • Side Effects of Antipsychotics
  • Symptoms of Antipsychotics Withdrawal
  • Bipolar Disorder
  • Symptoms of Bipolar Disorder
  • Mood Episode - A Major Symptom
  • Manic Episode Vs Depressive Episode
  • Causes of Bipolar Disorder
  • Types of Bipolar Disorder
  • Co-morbidities of Bipolar Disorder
  • Schizophrenia
  • Prevalence by Gender
  • Symptoms of Schizophrenia
  • Causes of Schizophrenia
  • Other CNS Disorders (Multiple Sclerosis, Attention Deficit Hyperactivity Disorder (ADHD), and Insomnia)
  • Multiple Sclerosis (MS)
  • List of Approved Drugs for MS
  • Patent Expiration Date/Year of the Major MS Drugs
  • Leading Multiple Sclerosis Drugs (2018): Sales in USD Million
  • New Approvals
  • Novartis Receives FDA Approval for Mayzent for Use in Multiple Sclerosis
  • Mavenclad Gains FDA Approval
  • Celgene Files NDA for Ozanimod
  • Ocrevus - The First Approved Drug for Primary Progressive Multiple Sclerosis (PPMS)
  • Multiple Sclerosis: Pipeline Analysis
  • Pipeline Drugs in Phase III for Multiple Sclerosis: As of October 2019
  • A Review of Multiple Sclerosis (MS)
  • Types of Multiple Sclerosis
  • Clinical Subtypes of Multiple Sclerosis (MS)
  • Prevalence of MS
  • Causes of MS
  • Myths Surrounding Multiple Sclerosis
  • Symptoms of MS
  • Diagnosis of MS
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Market Overview
  • Approved Drugs for ADHD: 2017
  • Sales of Vyvanse in 2018
  • Pipeline Drugs in Phase III for ADHD: As of October 2019
  • Select ADHD Drugs
  • Vyvanse
  • Concerta
  • Adderall
  • A Review of Attention Deficit Hyperactivity Disorder (ADHD)
  • Consequences of ADHD
  • What Leads to ADHD?
  • Insomnia
  • Overview
  • List of Approved Drugs for Insomnia
  • Pipeline Drugs for Insomnia: As of October 2019
  • Zolpidem
  • Eszopiclone
  • A Review of Insomnia
  • Prevalence of Insomnia
  • Therapies for Insomnia

2. FOCUS ON SELECT PLAYERS

  • AbbVie Inc. (USA)
  • Alkermes Plc. (Ireland)
  • Allergan Plc. (Ireland)
  • AstraZeneca Plc. (UK)
  • BIAL Group (Portugal)
  • Bristol-Myers Squibb (USA)
  • Eisai Co., Ltd. (Japan)
  • Endo Pharmaceuticals Inc. (USA)
  • Eli Lilly and Co. (USA)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Fabre-Kramer Pharmaceuticals, Inc. (USA)
  • GlaxoSmithKline (UK)
  • H. Lundbeck A/S (Denmark)
  • Johnson & Johnson (USA)
  • Janssen Pharmaceuticals, Inc. (USA)
  • Merck & Co., Inc. (USA)
  • Neurocrine Biosciences, Inc. (USA)
  • Novartis AG (Switzerland)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Pfizer, Inc. (USA)
  • Purdue Pharma L.P. (USA)
  • Sanofi (France)
  • Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Sunovion Pharmaceuticals, Inc. (USA)
  • Takeda Pharmaceutical Co., Ltd. (Japan)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • UCB S.A., (Belgium)

3. MARKET TRENDS & DRIVERS

  • Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
  • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market
  • Rising Healthcare Expenditure to Boost CNS Therapeutics Market
  • World Healthcare Expenditure (In US$ Trillion) for the Years 2017, 2019, 2021 & 2023
  • Per Capita Healthcare Expenditure (in $) by Select Countries for 2018
  • Growing Middle Class Population in Emerging Regions to Spur the Market
  • Global Middle Class Population (In Million) by Region for the Years 2020, 2025 and 2030
  • Global Middle Class Spending (US$ Trillion) by Region for the Years 2020, 2025, 2030
  • Growing Penetration of Generic Drugs Emerges as a Key Trait
  • Global Spending on Generic Drugs Vis-a-vis Branded Drugs (2019): Percentage Share Breakdown of Dollar Spending by Drug Category
  • Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market
  • Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point
  • Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines
  • Awareness Campaigns Launched by Pharma Companies to Benefit the Market
  • Music and Memory Programs Positively Impact Alzheimer's Disease (AD) and Related Dementia (ADRD) Patients
  • New Method to Isolate Active Compounds Related to Alzheimers from Plant Medicines

4. GLOBAL MARKET PERSPECTIVE

  • TABLE 1: CNS Therapeutics Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
  • TABLE 2: CNS Therapeutics Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017
  • TABLE 3: CNS Therapeutics Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025
  • TABLE 4: Pain Management (Segment) World Market by Region/Country in US$ Million: 2018 to 2025
  • TABLE 5: Pain Management (Segment) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
  • TABLE 6: Pain Management (Segment) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 7: Anti-Psychotics (Segment) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025
  • TABLE 8: Anti-Psychotics (Segment) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017
  • TABLE 9: Anti-Psychotics (Segment) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025
  • TABLE 10: Anti-Depressants (Segment) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025
  • TABLE 11: Anti-Depressants (Segment) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017
  • TABLE 12: Anti-Depressants (Segment) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 13: Anti-Epilepsy (Segment) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025
  • TABLE 14: Anti-Epilepsy (Segment) Market Historic Review by Region/Country in US$ Million: 2009 to 2017
  • TABLE 15: Anti-Epilepsy (Segment) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 16: Anti-Alzheimer's (Segment) World Market by Region/Country in US$ Million: 2018 to 2025
  • TABLE 17: Anti-Alzheimer's (Segment) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
  • TABLE 18: Anti-Alzheimer's (Segment) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 19: Anti-Parkinson's (Segment) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025
  • TABLE 20: Anti-Parkinson's (Segment) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017
  • TABLE 21: Anti-Parkinson's (Segment) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 22: Other Segments (Segment) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025
  • TABLE 23: Other Segments (Segment) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017
  • TABLE 24: Other Segments (Segment) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
  • Aging Population: A Strong Demographic Driver
  • North American Elderly Population by Age Group (1975-2050)
  • The Largest CNS Therapeutics Market Globally
  • Patent Expiries of Leading CNS Drugs in the US
  • Focus on Select Markets
  • Alzheimer's Market
  • Anti-depressant Drugs
  • Usage of Antidepressants Surges in the US
  • Anti-Epilepsy Market
  • Epilepsy - A Major Concern for the Healthcare Industry
  • A Glance at Epilepsy Statistics
  • Anti-Epilepsy Drugs
  • The US Epilepsy Market: Patent Expiry of Select Major Drugs
  • Epilepsy in Children
  • Growing Competition from Generics
  • Pain Management Market
  • Consumers in the US Seek Different Options for Chronic Pain Management
  • Neuropathic Pain Market
  • Anti-Psychotic Drugs Market
  • Mental Illnesses - Epidemiology
  • Facts & Figures
  • Lifetime Prevalence (%) of Bipolar Disorder in the US Population by Age Group
  • Popular Antipsychotic Drugs in the US
  • The US Anti-Psychotic Drugs Market by Indication (2019E): Percentage Share Breakdown of Value Sales
  • Surging Off-label Prescriptions
  • Generics Occupy Front Seat
  • Rising Antipsychotic Use among Children - A Cause of Concern
  • ADHD Market
  • Select Available ADHD Drugs in the US
  • The US ADHD Drugs Market by Drug Category (2019E): Market Share Breakdown of Total Prescription Sales for Stimulants (Amphetamines and Methylphenidates) and Non-Stimulants
  • The US ADHD Drugs Market by Type (2019E): Market Share Breakdown of Total Prescription Sales for Branded & Generic Drugs Groups
  • Adult ADHD Drugs Continue to Widen their Share
  • The US ADHD Drugs Market by Drug Category (2019E): Percentage Share Breakdown of Total Prescriptions for Adult & Pediatric Patient Groups
  • Market Analytics
  • TABLE 25: United States CNS Therapeutics Market Estimates and Projections in US$ Million by Segment: 2018 to 2025
  • TABLE 26: CNS Therapeutics Market in the United States by Segment: A Historic Review in US$ Million for 2009-2017
  • TABLE 27: United States CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • CANADA
  • CNS Diseases: Facts & Figures
  • Market Analytics
  • TABLE 28: Canadian CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018 to 2025
  • TABLE 29: Canadian CNS Therapeutics Historic Market Review by Segment in US$ Million: 2009-2017
  • TABLE 30: CNS Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025
  • JAPAN
  • TABLE 31: Japanese Market for CNS Therapeutics: Annual Sales Estimates and Projections in US$ Million by Segment for the Period 2018-2025
  • TABLE 32: CNS Therapeutics Market in Japan: Historic Sales Analysis in US$ Million by Segment for the Period 2009-2017
  • TABLE 33: Japanese CNS Therapeutics Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • CHINA
  • China: The Primary Market for CNS Drugs in Asia-Pacific
  • Select Anti-Schizophrenia Drugs Available in China
  • Other Available CNS Drugs in China
  • Market Analytics
  • TABLE 34: Chinese CNS Therapeutics Market Growth Prospects in US$ Million by Segment for the Period 2018-2025
  • TABLE 35: CNS Therapeutics Historic Market Analysis in China in US$ Million by Segment: 2009-2017
  • TABLE 36: Chinese CNS Therapeutics Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • EUROPE
  • Market Facts & Figures
  • European Patent Expiries of Select CNS Drugs
  • Pain Management Market
  • Neuropathic Pain Market Witnesses Foray of Generics
  • Anti-Psychotics Market
  • Demand for Antipsychotics for Bipolar Disorder Upbeat
  • Ageing Population Boosts Demand
  • 65+ Population as Percentage of Total Population for Major Countries in Europe: As on June 2019
  • Market Analytics
  • TABLE 37: European CNS Therapeutics Market Demand Scenario in US$ Million by Region/Country: 2018-2025
  • TABLE 38: CNS Therapeutics Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017
  • TABLE 39: European CNS Therapeutics Market Share Shift by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 40: European CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018-2025
  • TABLE 41: CNS Therapeutics Market in Europe in US$ Million by Segment: A Historic Review for the Period 2009-2017
  • TABLE 42: European CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • FRANCE
  • TABLE 43: CNS Therapeutics Market in France by Segment: Estimates and Projections in US$ Million for the Period 2018-2025
  • TABLE 44: French CNS Therapeutics Historic Market Scenario in US$ Million by Segment: 2009-2017
  • TABLE 45: French CNS Therapeutics Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • GERMANY
  • TABLE 46: CNS Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Segment for the Period 2018-2025
  • TABLE 47: German CNS Therapeutics Historic Market Analysis in US$ Million by Segment: 2009-2017
  • TABLE 48: German CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • ITALY
  • Market Snapshots
  • Market Analytics
  • TABLE 49: Italian CNS Therapeutics Market Growth Prospects in US$ Million by Segment for the Period 2018-2025
  • TABLE 50: CNS Therapeutics Historic Market Analysis in Italy in US$ Million by Segment: 2009-2017
  • TABLE 51: Italian CNS Therapeutics Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • UNITED KINGDOM
  • NICE Recommendations on CNS Therapeutics
  • Market Analytics
  • TABLE 52: United Kingdom Market for CNS Therapeutics: Annual Sales Estimates and Projections in US$ Million by Segment for the Period 2018-2025
  • TABLE 53: CNS Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Million by Segment for the Period 2009-2017
  • TABLE 54: United Kingdom CNS Therapeutics Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • SPAIN
  • TABLE 55: Spanish CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018 to 2025
  • TABLE 56: Spanish CNS Therapeutics Historic Market Review by Segment in US$ Million: 2009-2017
  • TABLE 57: CNS Therapeutics Market in Spain: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025
  • RUSSIA
  • TABLE 58: Russian CNS Therapeutics Market Estimates and Projections in US$ Million by Segment: 2018 to 2025
  • TABLE 59: CNS Therapeutics Market in Russia by Segment: A Historic Review in US$ Million for 2009-2017
  • TABLE 60: Russian CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • REST OF EUROPE
  • TABLE 61: Rest of Europe CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018-2025
  • TABLE 62: CNS Therapeutics Market in Rest of Europe in US$ Million by Segment: A Historic Review for the Period 2009-2017
  • TABLE 63: Rest of Europe CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • ASIA-PACIFIC
  • India & China Offer Significant Growth Opportunities
  • Growing Antipsychotics Market in Asia
  • Market Analytics
  • TABLE 64: Asia-Pacific CNS Therapeutics Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
  • TABLE 65: CNS Therapeutics Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017
  • TABLE 66: Asia-Pacific CNS Therapeutics Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 67: CNS Therapeutics Market in Asia-Pacific by Segment: Estimates and Projections in US$ Million for the Period 2018-2025
  • TABLE 68: Asia-Pacific CNS Therapeutics Historic Market Scenario in US$ Million by Segment: 2009-2017
  • TABLE 69: Asia-Pacific CNS Therapeutics Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • AUSTRALIA
  • TABLE 70: CNS Therapeutics Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Segment for the Period 2018-2025
  • TABLE 71: Australian CNS Therapeutics Historic Market Analysis in US$ Million by Segment: 2009-2017
  • TABLE 72: Australian CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • INDIA
  • TABLE 73: Indian CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018 to 2025
  • TABLE 74: Indian CNS Therapeutics Historic Market Review by Segment in US$ Million: 2009-2017
  • TABLE 75: CNS Therapeutics Market in India: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025
  • SOUTH KOREA
  • TABLE 76: CNS Therapeutics Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Segment for the Period 2018-2025
  • TABLE 77: South Korean CNS Therapeutics Historic Market Analysis in US$ Million by Segment: 2009-2017
  • TABLE 78: CNS Therapeutics Market Share Distribution in South Korea by Segment: 2009 VS 2019 VS 2025
  • REST OF ASIA-PACIFIC
  • TABLE 79: Rest of Asia-Pacific Market for CNS Therapeutics: Annual Sales Estimates and Projections in US$ Million by Segment for the Period 2018-2025
  • TABLE 80: CNS Therapeutics Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Segment for the Period 2009-2017
  • TABLE 81: Rest of Asia-Pacific CNS Therapeutics Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • LATIN AMERICA
  • TABLE 82: Latin American CNS Therapeutics Market Trends by Region/Country in US$ Million: 2018-2025
  • TABLE 83: CNS Therapeutics Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017
  • TABLE 84: Latin American CNS Therapeutics Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025
  • TABLE 85: Latin American CNS Therapeutics Market Growth Prospects in US$ Million by Segment for the Period 2018-2025
  • TABLE 86: CNS Therapeutics Historic Market Analysis in Latin America in US$ Million by Segment: 2009-2017
  • TABLE 87: Latin American CNS Therapeutics Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • ARGENTINA
  • TABLE 88: Argentinean CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018-2025
  • TABLE 89: CNS Therapeutics Market in Argentina in US$ Million by Segment: A Historic Review for the Period 2009-2017
  • TABLE 90: Argentinean CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • BRAZIL
  • TABLE 91: CNS Therapeutics Market in Brazil by Segment: Estimates and Projections in US$ Million for the Period 2018-2025
  • TABLE 92: Brazilian CNS Therapeutics Historic Market Scenario in US$ Million by Segment: 2009-2017
  • TABLE 93: Brazilian CNS Therapeutics Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • MEXICO
  • TABLE 94: CNS Therapeutics Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Segment for the Period 2018-2025
  • TABLE 95: Mexican CNS Therapeutics Historic Market Analysis in US$ Million by Segment: 2009-2017
  • TABLE 96: Mexican CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • REST OF LATIN AMERICA
  • TABLE 97: Rest of Latin America CNS Therapeutics Market Estimates and Projections in US$ Million by Segment: 2018 to 2025
  • TABLE 98: CNS Therapeutics Market in Rest of Latin America by Segment: A Historic Review in US$ Million for 2009-2017
  • TABLE 99: Rest of Latin America CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • MIDDLE EAST
  • TABLE 100: The Middle East CNS Therapeutics Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
  • TABLE 101: CNS Therapeutics Market in the Middle East by Region/Country in US$ Million: 2009-2017
  • TABLE 102: The Middle East CNS Therapeutics Market Share Breakdown by Region/Country: 2009, 2019, and 2025
  • TABLE 103: The Middle East CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018 to 2025
  • TABLE 104: The Middle East CNS Therapeutics Historic Market by Segment in US$ Million: 2009-2017
  • TABLE 105: CNS Therapeutics Market in the Middle East: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025
  • IRAN
  • TABLE 106: Iranian Market for CNS Therapeutics: Annual Sales Estimates and Projections in US$ Million by Segment for the Period 2018-2025
  • TABLE 107: CNS Therapeutics Market in Iran: Historic Sales Analysis in US$ Million by Segment for the Period 2009-2017
  • TABLE 108: Iranian CNS Therapeutics Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • ISRAEL
  • TABLE 109: Israeli CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018-2025
  • TABLE 110: CNS Therapeutics Market in Israel in US$ Million by Segment: A Historic Review for the Period 2009-2017
  • TABLE 111: Israeli CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • SAUDI ARABIA
  • TABLE 112: Saudi Arabian CNS Therapeutics Market Growth Prospects in US$ Million by Segment for the Period 2018-2025
  • TABLE 113: CNS Therapeutics Historic Market Analysis in Saudi Arabia in US$ Million by Segment: 2009-2017
  • TABLE 114: Saudi Arabian CNS Therapeutics Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • UNITED ARAB EMIRATES
  • TABLE 115: CNS Therapeutics Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Segment for the Period 2018-2025
  • TABLE 116: United Arab Emirates CNS Therapeutics Historic Market Analysis in US$ Million by Segment: 2009-2017
  • TABLE 117: CNS Therapeutics Market Share Distribution in United Arab Emirates by Segment: 2009 VS 2019 VS 2025
  • REST OF MIDDLE EAST
  • TABLE 118: CNS Therapeutics Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Segment for the Period 2018-2025
  • TABLE 119: Rest of Middle East CNS Therapeutics Historic Market Analysis in US$ Million by Segment: 2009-2017
  • TABLE 120: Rest of Middle East CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • AFRICA
  • TABLE 121: African CNS Therapeutics Market Estimates and Projections in US$ Million by Segment: 2018 to 2025
  • TABLE 122: CNS Therapeutics Market in Africa by Segment: A Historic Review in US$ Million for 2009-2017
  • TABLE 123: African CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025

IV. COMPETITION